NEWS

A selection of articles about companies we have supported

2025

June 12, 2025

Cytovale's Rapid Diagnostic Slashes Sepsis Mortality by 39%, Peer-Reviewed Study Confirms

April 1, 2025

AIRNA Raises $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline

2024

October 30, 2024

Axonis Therapeutics Announces $115 Million Series A Financing

October 23, 2024

Merck buys cancer therapy developer Modifi Biosciences for up to $1.3B

October 10, 2024

Cytovale Completes $100 Million Series D Funding to Accelerate Commercial Expansion of its Rapid Sepsis Solution

JuLY 31, 2024

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines into the Clinic

June 12, 2024

GSK Enters Into A Multi-Year Data License Agreement With Ochre Bio To Further Investigate The Drivers Of Liver Disease

May 2, 2024

Cytovale's Diagnostic Test Demonstrates Strong Performance in Rapid Identification of Sepsis Risk, Peer-Reviewed Study Confirms

APRIL 22, 2024

Ochre Bio Announces Partnership With Boehringer Ingelheim To Develop Novel Regenerative Treatments For Patients With Advanced Liver Disease

2023

November 15, 2023

Cytovale Secures $84 Million Series C to Advance Commercialization of Transformative Sepsis Diagnostic Tool

OCTOBER 16, 2023

Modifi Bio Raises Additional $4.3 Million in Seed Funding

OCTOBER 4, 2023

Dimension Inx Announces First Surgical Cases Utilizing CMFlex™ Synthetic Bone Graft

August 1, 2023

Cytovale Announces Commercial Launch of IntelliSep® Sepsis Test, the First-of-its-Kind Diagnostic Tool for Emergency Departments

May 16, 2023

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

february 1, 2023

Dimension Inx Receives U.S. FDA 510(k) for CMFlex™ and Raises $12M Series A to Commercialize New Generation of Regenerative Therapeutics

january 18, 2023

FDA Clears Cytovale’s IntelliSep Sepsis Test, First in a New Class of Emergency Department-Focused Diagnostic Tools

2022

October 10, 2022

Ochre Bio Raises $30M Series A Financing for the Development of RNA Therapies for Chronic Liver Diseases

October 4, 2022

miRecule Enters into Strategic Collaboration with Sanofi to Accelerate Discovery and Development of Antibody-RNA Conjugate to Treat FSHD

MaY 26, 2022

Scioto Biosciences, Inc. Announces Positive Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed With Autism Spectrum Disorder

MaY 11, 2022

Ochre Bio Launches ‘Liver ICU’ in the United States to Evaluate Effects of RNA Therapies on Human Liver Performance

March 17, 2022

Cytovale IntelliSep Test Demonstrates Potential to Rapidly Risk-Stratify Suspected COVID-19 Patients in New Study

February 8, 2022

Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis

2021

October 13, 2021

Forbes: How Cytovale is Set to Transform the Fight Against Sepsis

October 5, 2021

Eli Lilly-Backed IpiNovyx Bio Closes $10M to Advance Immunoproteasome Inhibitors

August 19, 2021

Scioto Biosciences Announces First Patient Dosed in Phase Ib Study

June 29, 2021

Dimension Inx Issued Patent for “Tissue Papers” Regenerative Medicine Platform

June 2, 2021

Cytovale Begins Enrollment in FDA 510(k) Clinical Study of IntelliSep Sepsis Test

May 24, 2021

miRecule Inc. Closes $5.7M to Create Breakthrough RNA Therapies

April 19, 2021

New Study Demonstrates Potential of Cytovale IntelliSep Test in the Rapid Diagnosis of Sepsis

2020

December 15, 2020

Dimension Inx Featured Among "21 Chicago Startups to Watch in 2021”

August 11, 2020

Scioto Biosciences Closes Series B Investment from Genome & Company

August 10, 2020

miRecule adds Maryland Momentum Fund to its Seed Round

April 30, 2020

BARDA, Cytovale Launch Study to Diagnose Sepsis in Patients with COVID-19

March 10, 2020

Dimension Inx Issued US Patent for Biomaterials Design and 3D-Printing Manufacturing System

March 2, 2020

Dimension Inx Co-Founder and CSO Named Among 10 Influential Women in Engineering

2019

August 21, 2019

Scioto Biosciences Awarded $2.3 Million Phase II SBIR to Develop Novel Microbiome Therapy

April 18, 2019

Simergent Closes $3M Seed Round for Development of Affordable Home Dialysis System